ABL Bio financials at a glance

+ Portfolio

The revenue of ABL Bio is reported as 66 billion Won in the fiscal year 2023. The earnings were 103 Won per share in 2023, which was 27.16 higher than 2022. And about -41.73998 billion Won are reported as free cash flow in the financials of ABL Bio 2023. No dividends were paid to the shareholders of the ABL Bio stock KOSDAQ:A298380 in the financial year 2023.

₩66.00B

Revenue

₩103.00

Earnings Per Share

99.93%

Gross Margin %

₩7.00B

Free Cash Flow

Revenue

66,000.00

Earnings Per Share

103.00

Gross Margin %

99.93

Free Cash Flow

7,000.00

Financials

Year	Year	TTM	2023	2022	2018
Rev.	Revenue	N/A	₩66.00B	₩65.33B	₩1.26B
GM %	Gross Margin %	99.93%	99.93%	99.88%	91.63%
OM	Operating Margin	-5.50%	-3.99%	1.35%	0.00%
EPS	Earnings Per Share	₩-,166.28	₩103.00	₩81.00	₩-3,804.00
Div.	Dividends	N/A	₩0.00	₩0.00	₩0.00
PR %	Payout Ratio %	0	0	0	0
Sha.	Shares	N/AM	47.89M	47.79M	44.59M
OCF	Operating Cash Flow	N/A	₩-36,000.00M	₩47.00B	₩0.00M
FCF	Free Cash Flow	N/A	₩7.00B	₩46.00B	₩0.00M
FCFS	Free Cash Flow Per Share	₩27.99	₩-,714.95	₩1.47k	₩-,453.81

ABL Bio financials at a glance

Financials

Discover